Development and validation of SCOPE score: A clinical score to predict COVID-19 pneumonia progression to severe respiratory failure
Year: 2022
Type: article
Abstract: Most patients infected with SARS-CoV-2 (COVID-19) experience mild, non-specific symptoms, but many develop severe symptoms associated with an excessive inflammatory response. Elevated plasma concentrations of soluble urokinase plasminogen activator receptor (suPAR) provide early warning of progression to severe respiratory failure (SRF) or death, but access to suPAR testing may be limited. The Severe COvid Prediction Estimate (SCOPE) score, derived from circulating concentrations of C-reactive protein, D- dimers, interleukin-6, and ferritin among patients not receiving non-invasive or invasive mechanical ventilation during the SAVE-MORE study, offers predictive accuracy for progression to SRF or death within 14 days comparable to that of a suPAR concentration of ≥6 ng/mL (area under receiver operator characteristic curve 0.81 for both). The SCOPE score is validated in two similar independent cohorts. A SCOPE score of 6 or more is an alternative to suPAR for predicting progression to SRF or death within 14 days of hospital admission for pneumonia, and it can be used to guide treatment decisions.
Source: Cell Reports Medicine
Authors: Evangelos J. Giamarellos-Bourboulis, Garyfallia Poulakou, Aline de Nooijer, Haralampos Milionis, Simeon Metallidis, Michalis Ploumidis, Pinelopi Grigoropoulou, Aggeliki Rapti, Francesco Vladimiro Segala, Evangelos Balis, Efthymia Giannitsioti, Paola Rodari, Ilias Kainis, Zoi Alexiou, Emanuele Focà, Brollo Lucio, Nikoletta Rovina, Laura Scorzolini, Maria Dafni, Sofia Ioannou, Alessandro Tomelleri, Katerina Dimakou, Glykeria Tzatzagou, Maria Chini, Matteo Bassetti, Christina Trakatelli, George Tsoukalas, Carlo Selmi, Charilaos Samaras, Maria Saridaki, Athina Pyrpasopoulou, Elisabeth Kaldara, Ilias Papanikolaou, Aikaterini Argyraki, Karolina Akinosoglou, Marina Koupetori, Periklis Panagopoulos, George N. Dalekos, Mihai G. Netea
Institutions: National and Kapodistrian University of Athens, University General Hospital Attikon, Hellenic Institute for the Study of Sepsis, Radboud University Nijmegen, University of Ioannina, Aristotle University of Thessaloniki, General Hospital of Athens G. Genimatas, General Hospital of Athens Elpis, Sotiria General Hospital, Agostino Gemelli University Polyclinic, Istituti di Ricovero e Cura a Carattere Scientifico, Evangelismos Hospital, Tzaneion General Hospital, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, University of Brescia, Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani, Vita-Salute San Raffaele University, IRCCS Ospedale San Raffaele, Papageorgiou General Hospital, Ospedale Policlinico San Martino, University of Genoa, Humanitas University, IRCCS Humanitas Research Hospital, General Hospital Asklepieio Voulas, University of Patras, Democritus University of Thrace, University Hospital of Larissa, General Hospital of Larisa, Greece, University of Bonn
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $5,200
Funders: Amgen, Pfizer, Astellas Pharma US, Bayer, GlaxoSmithKline, Roche, Gilead Sciences, AbbVie, Meso Scale Diagnostics, ViiV Healthcare, CymaBay Therapeutics, Intercept Pharmaceuticals, Nabriva Therapeutics, Nederlandse Organisatie voor Wetenschappelijk Onderzoek, Novo Nordisk, National and Kapodistrian University of Athens, Shionogi, Angelini Pharma, Servier, Swedish Orphan Biovitrum, InflaRx, Johnson and Johnson, European Research Council
Award: G1079402765
OpenAlex ID: W4214647802